28 results about "Immediate release" patented technology

The present invention relates to pharmaceutical compositions, specifically bilayer tablet formulations containing mirabegron and solifenacin succinate. The invention particularly addresses improvements in in-vitro release of solifenacin succinate in immediate release layer by improved manufacturing processes.

Provided herein are pharmaceutical formulations comprising glucokinase activator, or a prodrug, or a pharmaceutically acceptable salt, an isotope labeled analogue, a crystalline form, a hydrate, a solvate, or a diastereomeric or enantiomeric form thereof and the use thereof for treating diseases; the pharmaceutical formulations are in the form of immediate-release formulations, extended-release formulations, or combination of immediate-release formulation and extended-release formulations. The pharmaceutical formulations achieved once-a-day therapy for some diseases, in particular, type II Diabetes Mellitus with obesity. The pharmaceutical formulations exhibit sustained 24 hours of glucose-lowering effects. The pharmaceutical formulations also achieved lower Cmax, extended T1 / 2 as well as maintained similar bioavailability and increased MRT compared with commercial Dorzagliatin tablet, enhanced the pharmacology effect of restoring the glucose stimulated GLP-1 secretion in diabetes with obesity.

This application discloses a mild and long-lasting antibacterial tea tree oil cleaning composition, its preparation method, and its application. The composition comprises the following raw material components by mass percentage: 1.5%~3.5% tea tree oil microcapsules; 0.8%~2.5% rosemary-clove compound extract; 0.2%~0.8% protease; 10%~30% surfactant; 2%~5.5% auxiliaries; 0.2%~1% preservative; 0.2%~0.8% pH adjuster; and the balance being deionized water. This composition achieves a long-lasting antibacterial effect after washing through multiple mechanisms, including microcapsule sustained release, immediate release, and synergistic effect with plant extracts, effectively solving the technical problems of tea tree oil's volatility, easy oxidation, and short antibacterial duration.

The present invention relates to a pharmaceutical composition for oral administration, the pharmaceutical composition comprising: a) immediate-release granules comprising i. an active ingredient selected from the group consisting of valproic acid, semi-sodium valproic acid, sodium valproic acid, and magnesium valproic acid, and ii. a filler; and b) sustained-release pellets comprising: i. a pellet core comprising (1) an active ingredient selected from the group consisting of valproic acid, semi-sodium valproic acid, sodium valproic acid, and magnesium valproic acid, and (2) a filler; and ii. on the pellet core iii. A sustained-release pellet comprising a subcoat provided on the subcoat, the content of which is 10 to 20% by weight based on the weight of the pellet core and contains a film-forming agent, and iii. a sustained-release coating provided on the subcoat, the content of which is 25 to 100% by weight based on the weight of the pellet core coated with the subcoat and contains a film-forming agent, wherein the amount of active ingredient in the immediate-release granules accounts for 70 to 80% by weight of the total weight of active ingredients in the pharmaceutical composition, and the amount of active ingredient in the sustained-release pellets accounts for 20 to 30% by weight of the total weight of active ingredients in the pharmaceutical composition. In yet another aspect, the present invention relates to a method for producing a pharmaceutical composition and a pharmaceutical composition for use in a method of pretreatment of cancer.

The present invention relates to a pharmaceutical composition comprising nerandomilast, wherein the pharmaceutical composition is a tablet comprising nerandomilast and one or more pharmaceutically acceptable excipients, and wherein the tablet is an immediate release tablet. Further, the present invention relates to a method of manufacturing a pharmaceutical composition comprising nerandomilast.

Provided herein are methods and compositions for Sustained Release Energy, Mental Focus, and Physical Recovery Nutritional Supplement Blend, Dietary Supplement, Functional Food and Functional Beverage.

The present invention is directed to an in-the-bowl (ITB) system for dispensing at least two compositions into a toilet bowl at staggered time intervals comprising an ITB device arranged in the toilet bowl. The ITB device further includes an immediate release chamber having an inlet on a top surface and an outlet on a bottom surface and containing a first composition therein, a delayed release chamber having an inlet on a top surface, and a mechanism defines a triggering threshold and a terminating threshold, wherein the triggering threshold starts a flow out of the delayed release chamber at a staggered time interval, and the terminating threshold stops the flow out of the delayed release chamber allowing a predetermined amount of flush water to remain in the chamber creating a reservoir of a predetermined volume in the delayed release chamber.

This invention relates to the field of traditional Chinese medicine compound preparations, specifically to a traditional Chinese medicine compound nasal spray with both rapid-release and sustained-release effects, its preparation method, and its application. The preparation method of the traditional Chinese medicine compound nasal spray with both rapid-release and sustained-release effects includes the following steps: Step S1: Preparing the traditional Chinese medicine compound composition into a microemulsion solution; the traditional Chinese medicine compound composition contains volatile oils; Step S2: Making the microemulsion solution to volume with distilled water, then adjusting the osmotic pressure with sodium chloride solution, and adjusting the pH with hydrochloric acid solution. This invention combines rapid and long-lasting effects. One-fifth of the traditional Chinese medicine compound composition in the nasal spray has a rapid-release effect, and its rapid-release mechanism can produce a protective effect the moment the virus invades the nasal cavity; while the four-fifths of the drug sustained-release microspheres in the spray have a long-lasting mechanism, which can prolong the drug's action time, fully adapting to the "time-limited characteristic" of influenza virus transmission up to 48 hours, filling the gap in current similar nasal sprays that lack sustained-release effects.

This invention provides indole compound direct-release granules, comprising immediate-release granules and sustained-release granules. The immediate-release granules comprise an active pharmaceutical ingredient, a blank pellet core, a binder, and an anti-adhesion agent. The sustained-release granules comprise a drug-loaded layer and a sustained-release layer. The drug-loaded layer comprises the active pharmaceutical ingredient, a blank pellet core, a binder, and an anti-adhesion agent. The sustained-release layer comprises a sustained-release material, a plasticizer, and an anti-adhesion agent. The structural formula of the active pharmaceutical ingredient is shown below. This invention, by selecting blank pellet cores with smaller particle sizes, controlling the weight ratio of the active pharmaceutical ingredient to the blank pellet core, and increasing the weight gain of the sustained-release layer coating, obtains indole-based direct-release granules with better palatability, better sustained-release effect, and convenient administration.

The present invention provides a pharmaceutical tablet formulation of tenapanor that is chemically stable and soluble comprising greater than about 6% w / w of amorphous tenapanor in its bis-HCl form, an acidifying agent, an antioxidant, a disintegrant, a lubricant, a glidant, a filler, and an immediate release coating, wherein the total chloride content of the active ingredient is greater than 5.82% and the particle diameter distribution D50 is from about from about 18μm to about 22μm.

FIELD: pharmaceuticals.SUBSTANCE: relates to a formulation in the form of capsules for oral administration, for immediate release of a native collagen product. A formulation in the form of capsules for oral administration, for immediate release of a native collagen product, which is a gelatin capsule containing a central part, the central part contains a native collagen product from fish skins, ascorbic acid and an anti-caking component – calcium stearate, wt.%: native collagen product 83.08, ascorbic acid 14.96, calcium stearate 1.96.EFFECT: intended for oral administration for immediate release of the native collagen product.1 cl

The present application provides a kind of felodipine osmotic pump controlled-release tablets and preparation method thereof, the osmotic pump controlled-release tablet is composed of osmotic pump controlled-release tablet core and water-insoluble coating layer (single side laser punching), the weight percentage of the felodipine osmotic pump controlled-release tablet contains immediate-release coating layer, controlled-release coating layer, propelling coating layer, water-insoluble coating layer is (5~20) :(5~30) :(10~50) :(5~30).The present application also provides a kind of preparation method of felodipine osmotic pump controlled-release tablet and its application in treating hypertension.The formulation of the felodipine osmotic pump controlled-release tablet of the present application is reasonable, and production process is simple and easy to control;By replacing traditional controlled-release tablet polyethylene oxide with different povidone, the controllability of felodipine osmotic pump controlled-release tablet preparation is significantly improved, and the difficulty of cleaning in production is reduced.

This application relates to the field of pharmaceutical formulation technology, and particularly to a cefcaptin hydrochloride immediate-release / sustained-release composite formulation and its preparation method. The cefcaptin hydrochloride immediate-release / sustained-release composite formulation comprises a first particle and a second particle with a multi-layered coating structure. The first particle, from the inside out, comprises a first element particle (containing a first cefcaptin hydrochloride), a first isolation layer, a first sustained-release layer, an enteric coating layer, and a moisture-proof layer. The second particle, from the inside out, comprises a second element particle (containing a second cefcaptin hydrochloride), a second isolation layer, and a taste-masking layer. This cefcaptin hydrochloride immediate-release / sustained-release composite formulation of this application exhibits rapid release at pH 1–3 and slow release at pH 4–8, achieving a therapeutic effect comparable to traditional tablets administered three times daily after meals. Furthermore, this cefcaptin hydrochloride immediate-release / sustained-release composite formulation has low impurity content and high safety.

The present invention relates to an oral immediate-release formulation comprising ilaprazole with improved stability as an active ingredient and a method for preparing same, wherein the present invention relates to an oral immediate-release formulation and a method for preparing same, the oral immediate-release formulation comprising ilaprazole and a stabilizer in an inner core portion thereof and an antacid in an outer layer portion thereof, in which the oral immediate-release formulation has improved compounding stability by suppressing contact between the inner core portion and the outer layer portion through coating on the inner core portion, has excellent stability by minimizing the amount of related substances generated, and has a fast drug effect (the time to reach maximum blood concentration (Tmax) ranges from 0.3 hours to 0.8 hours) and excellent stability, through the rapid antacid effect of the antacid.

This invention relates to the field of pharmaceutical technology, specifically to a combination of traditional Chinese medicine (TCM) preparations for antibacterial and health-promoting treatment throughout the entire life cycle, and its method of use. The kit comprises three independent preparations: a rapid-release protective spray using Litsea cubeba essential oil nanoemulsion as a solvent, loaded with a compound alcoholic extract derived from Polygonum cuspidatum, Senecio scandens, Clematis chinensis, and Glycyrrhiza uralensis in a weight ratio of 4:3:1:1; a sustained-release repair gel patch using a thermosensitive poloxamer F127 and gelatin-sodium alginate double-network hydrogel as a matrix, encapsulating a concentrated aqueous extract obtained from freeze-dried powders of Polygonum cuspidatum, Portulaca oleracea, dried ginger, Bletilla striata, and honey in a weight ratio of 4:2:1:2:1; and a soluble healing-promoting bath film, a biodegradable film made from polyvinyl alcohol and carboxymethyl chitosan via a casting method, in which ultrafine powders of the core active pharmaceutical ingredient and nano-silver-bioglass composite material are dispersed. This application aims to construct a multi-layered, responsive product system from rapid protection to deep repair.

Disclosed are a gastroretentive double-layer sustained-release tablet, a preparation method therefor, and use thereof. An active ingredient of the gastroretentive double-layer sustained-release tablet is 3-[4-[4-(lH-benzotriazol-1-yl)butyl]piperazin-1-yl]benzisothiazole hydrochloride. Said tablet consists of two drug release layers comprising an immediate-release layer and a sustained-release layer. The immediate-release layer comprises the active ingredient, a filler I, and a disintegrant, and the sustained-release layer comprises the active ingredient, a filler II, a swelling material, a release blocker, a swelling enhancer, and a stabilizer. Said tablet can prolong the in vivo absorption window of the drug, maintain the plasma concentration, and prolong the in vivo half-life of the active ingredient.

The application provides a mosapride citrate stomach floating preparation, a preparation method thereof and application thereof. The mosapride citrate stomach floating preparation comprises first immediate-release particles, second immediate-release particles and sustained-release particles with a mass ratio of (1-2):(1-2):(1-2). The application uses the first immediate-release particles, the second immediate-release particles and the sustained-release particles in combination, and introduces mosapride citrate co-grinding materials into the second immediate-release particles and the sustained-release particles, so that the obtained preparation has a sustained-release effect. In addition, the application introduces a gas production layer coating and a retardation layer coating into the second immediate-release particles and the sustained-release particles in sequence, so that the mosapride citrate is prepared into a stomach floating preparation, the absorption of the mosapride citrate in the stomach and the upper part of the small intestine is prolonged, the blood drug concentration is stabilized, and the frequency of taking medicine is reduced. According to tests, the mosapride citrate stomach floating preparation provided by the application can be released smoothly within 2-12 hours, and has no burst release effect.

This invention provides a drug-carrying, integrated drug delivery system for modified Smilax glabranch starch, its preparation method, and its application, belonging to the field of pharmaceutical technology. The drug delivery system uses fresh Smilax glabranch starch as raw material. The PUL enzymatic method is used to debranch the starch, increasing the synthetic sites to reduce the clinical dosage. Hydroxybutyrylation modification and a "top-down" technique are used to form a uniform and stable drug-carrying, integrated drug delivery system for modified Smilax glabranch starch. The application is in the preparation of drugs for treating atopic dermatitis. This invention has the following advantages: debranched Smilax glabranch starch has multiple exposure sites, significantly improving butyrylation efficiency and resulting in a smaller dosage; the system can achieve colonic targeting, providing butyric acid through both endogenous and exogenous sources, achieving a dual release effect of immediate and controlled butyric acid production; the particle size is small, the distribution is uniform, the system is stable, and the PDI is 0.05~0.30; it effectively treats atopic dermatitis by reducing the inflammatory response.

An orally swallowable, immediate release tablet, comprising itopride or a pharmaceutically acceptable salt thereof as an active ingredient, characterized in that the tablet comprises granules containing the active ingredient, mannitol and optionally at least one additional pharmaceutically acceptable excipient, wherein the tablet does not contain lactose. Said tablet for use in prevention or treatment of gastrointestinal motility disorders. A method for manufacturing the orally swallowable, immediate release tablet according to any of the preceding claims, comprising: a) granulating itopride or a pharmaceutically acceptable salt thereof with mannitol and optionally at least one additional pharmaceutically acceptable excipient, b) optionally blending the granules obtained in step a) with at least one extra-granular pharmaceutically acceptable excipient, and c) compressing the granules from step a) or the blend from step b) into tablets.

This invention discloses a compound bilayer sustained-release formulation for treating arrhythmia, belonging to the field of pharmaceutical technology. The formulation uses two purified active monomers from natural plants as its core active components, employing a rapid-release and sustained-release bilayer structure design with strictly controlled dosages for each layer of active monomers. The two active monomers of this invention have clearly defined primary and secondary pharmacological functions, possessing both core targeted therapeutic efficacy and complementary secondary pharmacological effects. One component primarily regulates myocardial electrophysiology and intervenes in arrhythmias, while also exhibiting auxiliary activities such as coronary artery dilation and myocardial protection. The other component primarily functions for myocardial protection, microcirculation optimization, and myocardial damage repair, while also assisting in stabilizing heart rhythm. Furthermore, the first active monomer possesses dose-dependent cardiovascular pharmacological characteristics. This invention features a scientifically formulated, mild, and stable and sustained drug release, simultaneously achieving both rhythm regulation and myocardial protection. It solves the problems of existing formulations, such as single target, low safety, and limited therapeutic systems. The preparation process is simple and controllable, showing promising prospects for industrialization.

The present invention provides an orally administrable, aqueous, valacyclovir suspension having immediate release characteristics in acidic environment below pH 2; comprising crystalline valacyclovir hydrochloride hydrate loaded onto a cationic ion exchange resin particle (preferably of methacrylic acid copolymer with divinyl benzene), having carboxylic acid functional groups in a valacyclovir hydrochloride to IER weight / weight ratio of 1:0.4-1:0.6. The present invention also provides a powder for the preparation of the valacyclovir oral suspension, together with methods for the preparation of the powder, the suspension, their storage and use.

The application discloses a nicotine oral product and a preparation method thereof, and belongs to the technical field of novel tobacco products. The nicotine oral product comprises a nicotine bag inner core, a liquid-permeable bag body, and a first composition filled in the liquid-permeable bag body; and a mouth dissolving film shell, which is a closed shell made of a mouth dissolving film sheet, wherein the mouth dissolving film sheet comprises a second composition; wherein the mouth dissolving film shell is wrapped outside the nicotine bag inner core; and the first composition and the second composition both contain nicotine components. The nicotine oral product of the application realizes the dual-phase release characteristics of shell fast release and inner core slow release by organically combining the independent mouth dissolving film shell with the nicotine bag inner core, can quickly reach the effective concentration of nicotine, instantly meet the needs of consumers, maintain long-time stable release, and continuously satisfy the consumers, and simultaneously improves the storage stability and sensory experience.

The application provides a mosapride citrate sustained-release preparation, a preparation method thereof and application thereof. The mosapride citrate sustained-release preparation comprises first immediate-release granules, second immediate-release granules and sustained-release granules with a mass ratio of (1-2):(1-2):(1-2). The application can make the obtained preparation have a sustained-release effect by using the first immediate-release granules, the second immediate-release granules and the sustained-release granules in combination, and introducing mosapride citrate co-grinding materials into the second immediate-release granules. The test shows that the mosapride citrate sustained-release preparation provided by the application can be released smoothly within 2-12 hours without burst release effect. Meanwhile, the preparation process of the mosapride citrate sustained-release preparation provided by the application is simple, easy to realize, high in production efficiency, good in stability, and suitable for large-scale industrialized or industrialized production.